Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 04.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 15.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 02.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Com |
Stammdaten
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Unternehmen & Branche
| Name | Bone Biologics Corp |
|---|---|
| Ticker | BBLG |
| CIK | 0001419554 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies |
Wertpapier & Kennzahlen
| CUSIP | 098070113 |
|---|---|
| ISIN | US0980701132 |
| Typ | Common Stock |
| Marktkapitalisierung | 2,4 Mio. USD |
| Beta | 0,37 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -3,108,991 | -2.65 | 5,796,135 | 5,377,548 | |
| 2025-09-30 | 10-Q | -666,737 | -0.37 | 6,350,799 | 6,016,517 | |
| 2025-06-30 | 10-Q | -740,519 | -1.33 | 7,002,216 | 6,596,074 | |
| 2025-03-31 | 10-Q | -1,017,092 | -0.32 | 3,162,060 | 2,910,902 | |
| 2024-12-31 | 10-K | -4,112,420 | -28.96 | 3,861,369 | 3,483,657 | |
| 2024-09-30 | 10-Q | -941,002 | -14.21 | 4,065,818 | 3,792,416 | |
| 2024-06-30 | 10-Q | -783,733 | -4.02 | 3,193,464 | 2,908,957 | |
| 2024-03-31 | 10-Q | -865,970 | -1.31 | 3,839,574 | 3,674,948 | |
| 2023-12-31 | 10-K | -8,948,731 | -34.01 | 3,737,763 | 2,906,361 | |
| 2023-09-30 | 10-Q | -1,919,709 | -4.90 | 4,976,344 | 3,793,109 | |
| 2023-06-30 | 10-Q | -1,769,238 | -5.21 | 7,623,047 | 5,692,792 | |
| 2023-03-31 | 10-Q | -3,709,899 | -55.20 | 6,783,753 | 2,772,399 | |
| 2022-12-31 | 10-K | -1,484,620 | -31.15 | 8,495,237 | 5,947,308 | |
| 2022-09-30 | 10-Q | -1,219,277 | -3.53 | 5,200,977 | 4,401,502 | |
| 2022-06-30 | 10-Q | -469,304 | -1.36 | 5,658,881 | 5,588,245 | |
| 2022-03-31 | 10-Q | -689,499 | 6,093,714 | 6,038,801 | ||
| 2021-12-31 | 10-K | -1,610,685 | 6,675,365 | 6,575,456 | ||
| 2021-09-30 | 10-Q | -509,303 | 52,393 | -15,125,258 | ||
| 2021-06-30 | 10-Q | 1,070,000,000 | -491,898 | 4,438 | -14,615,955 | |
| 2021-03-31 | 10-Q | 1,070,000,000 | -431,747 | 71,165 | -14,124,057 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 46,167 | 0 | 46,167 | 563,231 | Neu | +100,0% | |
| DRW Securities, LLC | 23,576 | 0 | 23,576 | 34,185 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 11,083 | 0 | 11,083 | 16,070 | Neu | +100,0% | |
| UBS Group AG | 2,248 | 0 | 2,248 | 5,825 | Neu | +100,0% | |
| Tower Research Capital LLC (TRC) | 3,379 | 0 | 3,379 | 4,900 | Neu | +100,0% | |
| SBI Securities Co., Ltd. | 230 | 0 | 230 | 334 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 14 | 0 | 14 | 20 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| CITADEL ADVISORS LLC | 46,167 | 563,231 | 90.18 |
| DRW Securities, LLC | 23,576 | 34,185 | 5.47 |
| TWO SIGMA INVESTMENTS, LP | 11,083 | 16,070 | 2.57 |
| UBS Group AG | 2,248 | 5,825 | 0.93 |
| Tower Research Capital LLC (TRC) | 3,379 | 4,900 | 0.78 |
| SBI Securities Co., Ltd. | 230 | 334 | 0.05 |
| BANK OF AMERICA CORP /DE/ | 14 | 20 | 0.00 |